A Novel Approach to Discriminate Subgroups in Multiple Sclerosis
-
Mehrdad Farrokhi
,
Zahra Saadatpour
,
Elyas Fadaee
,
Leila Saadatpour
,
Ali Rezaei
,
Pedram Moeini
,
Ali Amani Beni
Abstract
Multiple sclerosis (MS) is an autoimmune disease of central nervous system. Since different types of immune cells are involved in MS pathogenesis, in this study we aimed to evaluate serum levels of several immunological components including soluble CD4 (sCD4), sCD8, sCD163, and immunoglobulins as markers of activity of T-cells, macrophages, and B-cells in different types of MS. Serum levels of sCD4, sCD8, and sCD163 of patients with relapsing-remitting MS (RRMS, n=61), primary progressive MS (PRMS, n=31), secondary progressive MS (SPMS, n=31), clinical isolated syndrome (CIS, n=31) and neuromyelitis optica (NMO, n=31), and healthy controls (n=49) were measured using enzyme-linked immunosorbent assay (ELISA). Serum levels of Ig-G, Ig-M, and Ig-A were determined using nephelometric technique. Serum levels of sCD4, sCD8, sCD163, Ig-G, Ig-M, and Ig-A were significantly different in five groups of cases (p<0.05). Furthermore, application of stepwise method of discriminant analysis yielded 4 significant discriminant functions of classification due to the presence of six levels of categorical variables in the analysis. The most important function explained 85.5% of the total variance with the correlation value of 0.79. Taken together, our preliminary analysis suggests that although we found some functions to discriminate most of the patients, further studies will be required to individuate immunological markers characterizing the different type of MS including RRMS, PPMS, SPMS, CIS and NMO as proved by the data on sCD4, sCD163, Ig-M, and Ig-G in blood.
1. Breij EC, Brink BP, Veerhuis R, van den Berg C, Vloet R, Yan R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008; 63(1):16-25.
2. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ.Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 2007;130(11):2800-15.
3. Zhang Z, Zhang ZY, Schittenhelm J, Wu Y, Meyermann R, Schluesener HJ. Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains. J Neuroimmunol 2011; 237(1-2):73-9.
4. Miron VE, Franklin RJ. Macrophages and CNS remyelination. J Neurochem 2014; 130(2):165-71.
5. Fabriek BO, Van Haastert ES, Galea I, Polfliet MM, Dopp ED, Van Den Heuvel MM, et al. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 2005; 51(4):297-305.
6. Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 2013; 16(9):1211-8.
7. Ponomarev ED, Shriver LP, Maresz K, Dittel BN.Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 2005;81(3):374-89.
8. Fabriek BO, Moller HJ, Vloet RP, van Winsen LM, Hanemaaijer R, Teunissen CE, et al. Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. J Neuroimmunol 2007; 187(1-2):179-86.
9. Moller HJ. Soluble CD163. Scand J Clin Lab Invest 2012; 72(1):1-13.
10. Sospedra M, Martin R. Immunology of multiple sclerosis.Annu Rev Immunol 2005; 23:683-747.
11. van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM- T412: results of a randomized, double-blind, placebo- controlled, MR-monitored phase II trial. Neurology 1997;49(2):351-7.
12. Investigators CT, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359(17):1786-801.
13. Raine CS. The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 1994; (36 Suppl):S61-72.
14. Brahic M, Bureau JF, Michiels T. The genetics of the persistent infection and demyelinating disease caused by Theiler's virus. Annu Rev Microbiol 2005; 59:279-98.
15. Munz C, Lunemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 2009; 9(4):246-58.
16. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2- responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994;179(3):973-84.
17. Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL. Soluble CD8 during T cell activation. J Immunol 1989; 142(7):2230-6.
18. Symons JA, Wood NC, di Giovine FS, Duff GW. Soluble CD8 in patients with rheumatic diseases. Clin Exp Immunol 1990; 80(3):354-9.
19. Famularo G, Giacomelli R, Sacchetti S, Danese C, Luciani AM, Perego MA, et al. Soluble CD8 antigen in systemic sclerosis. J Clin Lab Immunol 1990; 32(3):109-12.
20. Sawada S, Sugai S, Iijima S, Takei M, Paredes E, Hayama T, et al. Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjogren's syndrome. Am J Med 1992; 92(2):134-40.
21. Guseo A, Jellinger K. The significance of perivascular infiltrations in multiple sclerosis. J Neurol 1975;211(1):51-60.
22. Esiri MM. Immunoglobulin-containing cells in multiple- sclerosis plaques. Lancet 1977; 2(8036):478.
23. Archelos JJ, Hartung HP. Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci 2000; 23(7):317-27.
24. Stilund M, Reuschlein AK, Christensen T, Moller HJ, Rasmussen PV, Petersen T. Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis. PloS one 2014; 9(6):e98588.
25. Bruck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38(5):788-96.
26. Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation 2013; 10:35.
27. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132(Pt 5):1175-89.
28. Tsukada N, Matsuda M, Miyagi K, Yanagisawa N.Soluble CD4 and CD8 in the peripheral blood of patients with multiple sclerosis and HTLV-1-associated myelopathy. J Neuroimmunol 1991 Dec;35(1-3):285-93.
29. Franciotta D, Piccolo G, Zardini E, Bergamaschi R, Cosi V. Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone. Acta Neurol Scand 1997; 95(5):275-9.
30. Wandinger KP, Wessel K, Trillenberg P, Heindl N, Kirchner H. Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients. Acta Neurol Scand 1998; 97(6):359-65.
31. Chen Y, Li R, Wu AM, Shu YQ, Lu ZQ, Hu XQ. The complement and immunoglobulin levels in NMO patients. Neurological sciences. Neurol Sci 2014;35(2):215-20.
32. Aho K, Heliovaara M, Knekt P, Reunanen A, Aromaa A, Leino A, et al. Serum immunoglobulins and the risk of rheumatoid arthritis. Ann Rheum Dis 1997; 56(6):351-6.
33. Ohkubo T, Takei M, Mitamura K, Horie T, Fujiwara S, Shimizu K, et al. Increased soluble CD4 molecules and the role of soluble CD4 production in patients with rheumatoid arthritis. J Int Med Res 2001; 29(6):488-96.
34. Sun CC, Wu J, Wong TT, Wang LF, Chuan MT. High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities. Br J Dermatol 2000; 143(6):1235-40.
35. Di Cesare E, Previti M, Ingemi MC, Bagnato GF, Cucinotta D. High serum levels of soluble CD8 in insulin-dependent diabetes. Clin Exp Immunol 1994;95(2):283-6.
36. Spronk PE, ter Borg EJ, Huitema MG, Limburg PC, Kallenberg CG. Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 1994; 53(4):235-9.
| Files | ||
| Issue | Vol 15, No 6 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Multiple sclerosis Soluble CD4 Soluble CD8 Soluble CD163 Immunoglobulins | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
